In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Building renewables in Alberta just got a lot harder
Toxic truths about Agent Orange in Canadian military base
Celebrated Group of Seven sketches revealed to be fakes
Why measles infections are surging again
Documents reveal fired scientists shared information with China
What to know about Canada’s new Pharmacare bill
Filling Canada’s trades labour shortage with high school students
Why discount airlines keep going bust in Canada
The rise in exclusive deals between insurers and pharmacies
The Odysseus lunar landing and a new space race
The landmark decision on white nationalist terrorism
On the ground in Kharkiv, two years into the Russian invasion
Is Trudeau leading the Liberals to an election day shellacking?
Investigating Canada’s dependence on for-profit nursing
The Federal Housing Advocate on the national encampment crisis
The Alberta credit union betting on gold over government
Inside the power struggle over Rogers’ telecom empire
Palestinians fleeing Gaza face hurdles coming to Canada
The rising costs of pet ownership
China sets its sights on the Arctic
Create your
podcast in
minutes
It is Free
Front Burner
At Issue
The Daily
Today, Explained
Morning Wire